Drugs / GSK2130579A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01051063 | Dec 2009 → Apr 2016 | acute myeloid leukemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00725283 | Oct 2008 → Jun 2016 | acute myeloid leukemia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2130579A | “Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia” NCT00725283 ↗ |
| Modality | Other / unclassified | “recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)” NCT01051063 ↗ |
| Route | Intramuscular | “Intramuscular administration” NCT00725283 ↗ |
| Target | WT1 | “WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)” NCT00725283 ↗ |